Biotechnology-Based Natera Announces Partnership With Susan G. Komen®

Natera’s Signatera MRD test is backed by more than 185 peer reviewed publications covering multiple cancer types, including breast cancer. The company said the research highlights its continued focus on advancing cancer testing and precision medicine.

Susan G. Komen takes a comprehensive approach to breast cancer by supporting research, community health, patients, public policy, and global outreach.

The partnership also supports Natera’s ongoing breast cancer research, including studies exploring how MRD testing can help personalize treatment, guide care decisions, and improve patient outcomes.

Read More:California-Based AusperBio Raises $120M in Series C Funding

As part of the partnership, Natera will be the 2026 Premier National Series Sponsor of Komen’s Race for the Cure and MORE THAN PINK Walk events. Natera will support these events to raise breast health awareness, help patients and survivors, and promote Komen’s mission. The company will also continue supporting Komen’s patient education programs, including the “Know More” series.

“Our growing partnership with Susan G. Komen reflects Natera’s commitment to advancing science with urgency and ensuring that meaningful innovations reach the patients and clinicians who need them most,” said Minetta Liu, M.D., chief medical officer, oncology and early cancer detection, Natera.

“Natera's partnership helps strengthen our reach to fund breakthrough research, support patients and families, and deliver critical resources to communities across the country,” said Victoria Wolodzko Smart, senior vice president of mission, Susan G. Komen. “Together, we can help accelerate progress against breast cancer while ensuring that people facing the disease have access to the education, support, and advocacy they need.

About Natera

Founded in 2004, Natera is a global leader in cell free DNA testing and precision medicine, focusing on oncology, women’s health, and organ health. The company work's to make personalized genetic testing and diagnostics a standard part of healthcare, helping doctors detect health risks earlier, and provide more targeted treatment for better outcomes.

Read More:California-Based CivilGrid Raises $26M in Series A Funding